Coagulopathy of Coronavirus Disease 2019: A Case Series

Abstract

BACKGROUND: In Coronavirus disease 2019 (COVID-19), the main manifestations were fever, cough, and anosmia. AIM: We aimed to investigate coagulopathy and disseminated intravascular coagulation in severe COVID-19 patients. METHODS: Five cases of COVID-19 with coagulopathy have been reported. RESULTS: All patients presented with various main complaints such as fever, cough, shortness of breath, and diarrhea. An increase in D-dimer value was found in all cases, with an increase of 4–5 times from the upper limit of normal. All patients were evaluated with the IMPROVE-VTE and PADUA thrombotic risk assessment models. Thromboprophylaxis with low molecular weight heparin LMWH intensive dosage was given to four patients. However, one patient was not given thromboprophylaxis because of the high risk of bleeding. All cases were not given long-term thromboprophylaxis after the patients were discharged from the hospital. All hospitalized COVID-19 patients can be considered to give thromboprophylaxis unless contraindicated. Thromboprophylaxis is preferable to use LMWH with a dose adjusted to the severity of COVID-19. Administration of thromboprophylaxis after hospitalization may be considered in patients who have thromboembolic risk factors. CONCLUSION: More research is being encouraged to increase understanding of the prevention and treatment of thrombotic complications of COVID-19.

Coagulation parameters abnormalities and their relation to clinical outcomes in hospitalized and severe COVID-19 patients: prospective study

“…The derangements in the coagulation variables in COVID-19 patients and their prognostic value became research potentials 3 . Monitoring coagulation variables became an integral component of disease management as it may require additional interventions, and it can be associated with unwanted outcomes 4 .…”

Clinical Outcome in Patients with COVID-19 and Comparison to Serum LDH and D-dimer Levels

“…It may lead to heart injury and renal failure. [18][19][20] The presence of thrombocytopenia and high D-dimer values in patients with severe COVID-19 suggests that a hypercoagulable condition may be responsible for the severity of the illness and death. 21,22 In a study by Mohsin et al conducted in Iraq, 29 they discovered that patients with severe coronavirus symptoms had much higher levels of LDH and D-dimer than those with no coronavirus infection or an infection with very moderate symptoms (p = 0.001).…”

“…19 Monitoring coagulation factors has become a crucial part of illness treatment since it may call for extra therapies and may result in unfavourable effects. 20 The aim of the current study was to determine how laboratory measures, specifically D-Dimer and LDH combined, predict the severity of COVID-19 patients and estimate how these parameters relate to clinical outcomes in COVID-19 patients who are hospitalised.…”